Home » Newsletters » BioWorld Science

BioWorld Science

July 18, 2018

View Archived Issues

CRISPR reprograms T cells

Good-enough HCV vaccine could reduce transmission

BAFF and Beffs

Hot flashes are hypothalamic

Hearing light, no synesthesia required

ONO-8590580, a GABA(A)-alpha5 negative allosteric modulator enhancing hippocampal memory function

Novel CD-1db/db mouse model of type 2 diabetes with progressive kidney fibrosis

Discovery of novel PET tracer for imaging CSF-1R in the brain

First cohort dosed in phase I study of OMS-527

Blade Therapeutics initiates phase I study of BLD-2660

Cellectar reports 94% reduction in tumor volume in patient

Regeneron initiates phase I study of REGN-4659 plus cemiplimab in patients with NSCLC

Enrollment ongoing in phase II study of F-901318

Reactivated X chromosome produces functional Rett protein in mouse brains

Chinese researchers present preclinical data for DB-213, an HIV-1 replication inhibitor

Capricor Therapeutics' CAP-2003 to be studied for potential for trauma-related injuries

Voyager's VY-AADC program in Parkinson's guided by FDA and new phase I posterior trajectory data

FDA approves Symtuza for HIV-1 infection

Phase Ib results support Poxel's plans for phase II with PXL-770 in NASH

Roche and C4 Therapeutics patent EGFR mutant inhibitors

Pulmatrix reports data from Part 3 of first-in-human study of Pulmazole

Ono Pharmaceutical synthesizes PTK6 inhibitors

Italian researchers identify compounds for kinetoplastid infections

Oligomerix presents tau aggregation inhibitors

Merck & Co. divulges FFA1 receptor agonists

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 17, 2026.
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...